Tema Etfs LLC Takes $1.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Tema Etfs LLC bought a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 30,811 shares of the company's stock, valued at approximately $1,113,000.

Several other institutional investors have also recently made changes to their positions in the stock. Sphera Funds Management LTD. purchased a new stake in SpringWorks Therapeutics in the fourth quarter valued at approximately $3,613,000. ProShare Advisors LLC raised its position in shares of SpringWorks Therapeutics by 31.7% during the 4th quarter. ProShare Advisors LLC now owns 22,883 shares of the company's stock valued at $827,000 after buying an additional 5,503 shares in the last quarter. Patient Square Capital LP bought a new stake in shares of SpringWorks Therapeutics during the 4th quarter worth $3,365,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in SpringWorks Therapeutics by 2.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,013 shares of the company's stock worth $1,591,000 after acquiring an additional 931 shares in the last quarter. Finally, Integral Health Asset Management LLC purchased a new stake in SpringWorks Therapeutics during the fourth quarter valued at about $3,613,000.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX traded up $0.18 during mid-day trading on Friday, reaching $46.45. The stock had a trading volume of 4,132,770 shares, compared to its average volume of 2,155,629. The company has a fifty day moving average price of $43.62 and a 200 day moving average price of $42.59. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00. The stock has a market cap of $3.50 billion, a PE ratio of -13.35 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $49.09 million during the quarter, compared to the consensus estimate of $64.19 million. As a group, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on SWTX. TD Cowen reiterated a "hold" rating and set a $47.00 price objective (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Guggenheim restated a "neutral" rating and issued a $47.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Cowen cut SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday, April 29th. HC Wainwright reiterated a "neutral" rating and issued a $47.00 price objective (down from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, April 30th. Finally, Barclays reaffirmed an "equal weight" rating and issued a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Hold" and an average price target of $52.57.

Insider Activity at SpringWorks Therapeutics

In related news, CEO Saqib Islam sold 49,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the completion of the transaction, the chief executive officer now directly owns 954,869 shares in the company, valued at approximately $51,792,094.56. The trade was a 4.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Badreddin Edris sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the sale, the chief operating officer now owns 169,712 shares in the company, valued at approximately $9,203,481.76. The trade was a 10.54% decrease in their position. The disclosure for this sale can be found here. 7.83% of the stock is owned by company insiders.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.